News >

Mok Discusses Dacomitinib Potency in Frontline EGFR+ NSCLC

Brandon Scalea
Published: Monday, Aug 13, 2018

Tony S. Mok, MD

Tony S. Mok, MD
Results from the phase III ARCHER 1050 trial presented at the 2018 ASCO Annual Meeting showed that the second-generation EGFR tyrosine kinase inhibitor (TKI) dacomitinib improved overall survival (OS) compared with a standard first-generation TKI in patients with EGFR-mutant non–small cell lung cancer (NSCLC).

During a median follow-up time of 31.3 months, the OS probability for patients treated with dacomitinib was 56.2% versus 46.3% for those who received gefitinib. In the phase III trial, patients were randomized to orally receive either 45 mg/day of dacomitinib or 250 mg/day of gefitinib.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication